Othair Prothena Limited

Prothena Biosciences Limited

Wyeth

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Janssen Sciences Ireland Uc

Janssen Alzheimer Immunotherapy

Wagner Marcelo Zago

Tarlochan S Nijjar

Robin McDaid Barbour

Gene Kinney

Frédérique Bard

Michael Skov

Philip James Dolan, Iii

Andriani Ioannou

Carol Karp

Olaf Mundigl

Lioudmila Tchistiakova

Jens Niewoehner

Georg Tiefenthaler

Davinder Gill

James Callaway

Angela Widom

Jack Steven Jacobsen

Ivan Lieberburg

Kate Dora Games

Michael Grundman

Ronald Black

Tom Purcell

Keith M Gregg

Lars Ekman

Sally Schroeter

Gene G Kinney

Manuel J Buttini

Radhika Tripuraneni

Kate Dora Games-Thiel

Tarlochan S Niijar

Gennaro Pagano

Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

Anti-Aβ antibodies

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.

Multi-epitope vaccine for the treatment of Alzheimer's disease

Antibody formulations and methods useful for treatment of patients with AL amyloidosis.

Methods of treating AL amyloidosis

The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab.

Treatment of Parkinson's disease

The invention provides antibodies that specifically bind sortilin. The antibodies inhibit or delay pathologies associated with changes in progranulin levels and associated symptomatic deterioration.

Antibodies recognizing sortilin

Humanized antibodies recognizing sortilin

Anti-abeta antibodies

Anti-Abeta antibodies

The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).

Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein

Growing community of inventors

San Carols, CA, United States of America

Wagner Marcelo Zago